Clinical Trials Logo

Clinical Trial Summary

This is a study of a medical procedure that utilizes a commercially available catheter (the Bullfrog® Micro-Infusion Device) to locally deliver a commercially available anti-inflammatory drug (dexamethasone sodium phosphate injection) around the deep veins after DVT recanalization, where DVT symptoms were present for at least 14 days and no more than 60 days prior to recanalization. The goal of the study is to see if local anti-inflammation helps prevent re-thrombosis of the blood vessel and improvement in symptoms for up to 24 months after the initial DVT recanalization procedure.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT04858776
Study type Interventional
Source Mercator MedSystems, Inc.
Status Not yet recruiting
Phase Phase 2
Start date June 1, 2021
Completion date August 1, 2023